Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
24.52
+0.42 (1.74%)
Mar 10, 2026, 9:33 AM HKT
-9.02%
Market Cap 9.81B
Revenue (ttm) 2.75B
Net Income (ttm) 279.32M
Shares Out 226.13M
EPS (ttm) 1.20
PE Ratio 20.05
Forward PE n/a
Dividend 1.13 (4.70%)
Ex-Dividend Date n/a
Volume 127,200
Average Volume 111,554
Open 23.78
Previous Close 24.10
Day's Range 23.58 - 24.60
52-Week Range 21.70 - 34.35
Beta 0.52
RSI 34.46
Earnings Date Mar 21, 2026

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 2,156
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6826
Full Company Profile

Financial Performance

In 2025, HKG:6826's revenue was 2.47 billion, a decrease of -7.71% compared to the previous year's 2.68 billion. Earnings were 251.01 million, a decrease of -40.30%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.